A, H., T, T., M, H., K, K., J, T., M, A., . . . T, K. (2026). Real-World Comparison of First-Line Atezolizumab plus Bevacizumab and Durvalumab plus Tremelimumab for Unresectable Hepatocellular Carcinoma. Liver cancer. https://doi.org/10.1159/000550924
Chicago Style (17th ed.) CitationA, Hiraoka, et al. "Real-World Comparison of First-Line Atezolizumab Plus Bevacizumab and Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma." Liver Cancer 2026. https://doi.org/10.1159/000550924.
MLA (9th ed.) CitationA, Hiraoka, et al. "Real-World Comparison of First-Line Atezolizumab Plus Bevacizumab and Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma." Liver Cancer, 2026, https://doi.org/10.1159/000550924.
Warning: These citations may not always be 100% accurate.
